IngredientesMagnesium is a chemical element with the symbol Mg and atomic number 12. Magnesium (Mg2+) is the fourth most abundant cation in the human body and a critical cofactor in hundreds of enzymatic reactions that regulate energy metabolism, neuromuscular function, cardiovascular health, bone integrity, immune defense, and psychological well-being. Magnesium is an abundant mineral in the body, is naturally present in many foods, available as a dietary supplement, and present in some medicines such as antacids and laxatives.
The earliest known reference to magnesium was in the form of a magnesium-containing mineral called magnesite, which was discovered in ancient Greece. The name "magnesium" is derived from Magnesia, a district in ancient Greece where this mineral was found. Joseph Black, a Scottish chemist, was pivotal in identifying magnesium as an element in the 1750s, although Sir Humphry Davy was the first to isolate it in 1808.
Magnesium is part of the green pigment chlorophyll, which is vital for photosynthesis in plants; therefore green leafy vegetables are a good dietary source for magnesium. Magnesium is also found in high concentrations in fish, dairy products, meats, whole grains, and nuts. Additionally chocolate, coffee, and hard water contain a good amount of magnesium.
Magnesium is commonly extracted from seawater, where it is the third most common component. As a dietary supplement, magnesium is found naturally in many foods, including legumes, nuts, seeds, whole grains, and green leafy vegetables.
Magnesium is available in a wide range of supplemental forms, broadly classified as organic and inorganic salts. Magnesium supplements are broadly categorized into organic and inorganic compounds. Organic forms, such as magnesium citrate, glycinate, lactate, or malate, involve magnesium chelated to organic molecules like amino acids or organic acids. These forms are generally more soluble and have higher bioavailability. Inorganic forms, such as magnesium oxide, sulphate, and chloride, are bound to inorganic salts and tend to have lower solubility and absorption rates.
Magnesium is available in multivitamin-mineral supplements and other dietary supplements. Forms of magnesium in dietary supplements that are more easily absorbed by the body are magnesium aspartate, magnesium citrate, magnesium lactate, and magnesium chloride. Magnesium is also included in some laxatives and some products for treating heartburn and indigestion.
Several ancient authors, in particular Hippocrates II, Claudius Galen, and Soran of Ephesus, described the profound laxative effect of sea salt and of crushed dolomite, as well as a positive effect on the psyche of drinking mineral waters from sources that were found by modern scientists to be rich in magnesium, lithium, and bromine.
The laxative effect of mineral waters from some sources rich in magnesium, or of salts that were extracted from such sources, was known in the Middle Ages. Later, Paracelsus discovered that these salts could be useful not only as a laxative, but also as a sedative. In 1707, Massimiliano Valentini first obtained magnesium oxide, which immediately found its use in medicine, as an antacid, as a mild laxative, and as a skin powder.
Magnesium was used as a curative as early as ancient times, in the form of laxatives and Epsom salts. In the 1600s, water from the famous Epsom spring discovered in England was a popular curative, used as an internal remedy and purifier of the blood. In the 17th century, the healing spring of Epsom, England became famous. The water there was rich in magnesium sulfate, and locals quickly noticed its cleansing and calming effects.
The ancient Greeks and Romans used magnesite for medicinal purposes, believing that it had healing properties. In ancient Egypt, records illustrate the use of mineral-rich salts, including magnesium, for mummification and medicinal remedies.
Magnesium has been recognized for its health benefits since ancient times, with its use documented in traditional medicine systems such as Ayurveda and Traditional Chinese Medicine (TCM). In traditional Chinese medicine (TCM), balance is everything. Magnesium often appeared in mineral-based powders and tonics used to restore harmony in the body. Magnesium salts helped clear heat from the body, reduce inflammation, and regulate digestion. Ayurveda, India's ancient system of medicine, also used magnesium-rich clays and salts. Practitioners used them to calm the skin, support detoxification, and reduce anxiety. Rock salt, which contains magnesium, was often part of digestive and skin remedies.
In 1926, Jacques Leroy was the first to prove the vital importance of magnesium for the physiology of animals.
Unlike botanical supplements that contain diverse phytochemicals, magnesium's activity resides in the Mg2+ ion itself. Its biological roles are extensive and multifaceted.
Magnesium is a cofactor in more than 300 enzyme systems that regulate diverse biochemical reactions in the body, including protein synthesis, muscle and nerve function, blood glucose control, and blood pressure regulation. Magnesium is required for energy production, oxidative phosphorylation, and glycolysis.
Phosphoryl transfer is a fundamental reaction in cellular signaling and metabolism that requires Mg2+ as an essential cofactor. While the primary function of Mg2+ is electrostatic activation of substrates such as ATP, the full spectrum of catalytic mechanisms exerted by Mg2+ is not completely known. The divalent cation activates the attacked phosphoryl group and/or the leaving group of ATP by charge neutralization, electron withdrawal, and by adjustment of the conformation of the polyphosphate chain.
Mg2+ plays a pivotal role in transition state formation during ATP synthesis catalyzed by ATP synthases, a role that involves both its preferential coordination with phosphate and the repositioning of the P-loop. This makes magnesium indispensable for cellular energy generation across virtually all tissues.
Mg2+ is an essential cofactor for activation of enzymatic ATP hydrolysis in the Na,K-ATPase without being transported through the cell membrane. Moreover, experimental evidence has been collected showing that Mg2+ ions have a regulatory effect on ion transport by interacting with the cytoplasmic side of the ion pump.
Magnesium is involved in bone formation and influences the activities of osteoblasts and osteoclasts. Magnesium also affects the concentrations of both parathyroid hormone and the active form of vitamin D, which are major regulators of bone homeostasis.
Magnesium modulates neuronal excitability through voltage-gated calcium antagonism and N-methyl-D-aspartate (NMDA) receptor blockade, thereby attenuating cortical spreading depression and trigeminovascular activation, both core migraine mechanisms.
One hypothesized mechanism eliciting beneficial effects on health outcomes is the action of magnesium on serum inflammatory parameters. Among 2,484 papers initially screened, 17 randomized controlled trials (889 participants; mean age: 46 years; females: 62.5%) were included in a 2022 meta-analysis. Generally, a low risk of bias was present. In meta-analysis, magnesium supplementation significantly decreased serum C-reactive protein (CRP) and increased nitric oxide (NO) levels.
In 2022, the U.S. Food and Drug Administration (FDA) approved a qualified health claim for conventional foods and dietary supplements that contain magnesium. One example of this claim states, "Consuming diets with adequate magnesium may reduce the risk of high blood pressure (hypertension). However, FDA has concluded that the evidence is inconsistent and inconclusive." FDA also specifies that the foods and dietary supplements that carry this claim on their labels must provide at least 84 mg of magnesium per serving and, for dietary supplements, no more than 350 mg.
The latest evidence review by the United States FDA in 2022 identified supportive yet inconclusive evidence that diets with adequate magnesium reduce hypertension. Of the meta-analyses conducted to date, 2 of those reviewing randomized controlled trials found small yet significant reductions in systolic BP (SBP) and diastolic BP (DBP), 1 found magnesium supplementation reduced DBP but not SBP among hypertensive individuals, and 1 review found no effect of oral magnesium supplementation on BP.
The Atherosclerosis Risk in Communities Study assessed heart disease risk factors and levels of serum magnesium in a cohort of 14,232 White and African-American men and women age 45 to 64 years at baseline. This large prospective study represents some of the more robust epidemiological evidence in this area.
Evidence strength: Epidemiological associations are reasonably consistent for cardiovascular benefit; however, RCT evidence for blood pressure reduction is mixed, and the FDA characterizes the totality as inconsistent and inconclusive.
Previous studies have demonstrated that diabetes is often accompanied with lower magnesium status. Magnesium has been implicated in the pathophysiology of type 2 diabetes, with magnesium deficiency contributing to insulin resistance and impaired glucose metabolism.
Pooled analyses of 24 randomized controlled trials with 1,325 type 2 diabetes (T2D) individuals revealed that subjects who received magnesium supplementation had statistically significant reductions in fasting plasma glucose, glycated hemoglobin, systolic blood pressure, and diastolic blood pressure.
A meta-analysis of 23 randomized controlled trials involving 1,345 participants evaluated the effects of magnesium supplementation on glycemic control in type 2 diabetes mellitus. Magnesium supplementation significantly increased serum magnesium levels and reduced fasting blood glucose levels; however, the impact on glycated hemoglobin was minimal. Subgroup analysis showed a greater reduction in glycated hemoglobin among participants aged ≥65 years and those receiving longer durations of supplementation.
Despite the abundance of research, the efficacy of magnesium supplements for glycemic control in diabetic patients remains inconclusive.
Following magnesium supplementation in one systematic review and meta-analysis, a significant improvement was observed in fasting plasma glucose, HDL cholesterol, LDL cholesterol, plasma triglycerides, and systolic blood pressure. During subgroup analysis, a more beneficial effect of magnesium supplementation was observed in diabetic subjects with hypomagnesemia.
In a small randomized controlled trial conducted in 2018 with 42 patients, researchers found that for patients with type 2 diabetes, oral magnesium supplementation may improve glycemic control indicators and reduce insulin resistance. Specifically, participants who took 250 mg a day of elemental magnesium for 3 months saw significant improvements in insulin levels and HbA1c.
Evidence strength: Moderate. Multiple meta-analyses of RCTs show statistically significant reductions in fasting blood glucose. The effect on HbA1c is smaller and less consistent. Benefits appear most robust in individuals with existing hypomagnesemia. Larger, longer-term RCTs are needed before definitive clinical guidelines can be issued.
Magnesium, in particular, is popular on social media for the treatment of anxiety and insomnia. Meanwhile, preclinical studies support associations between magnesium status, sleep quality, and symptoms of anxiety. The extent to which these claims are evidence-based is unclear.
A systematic review in 2021 found only three randomized controlled trials, with 151 total participants, assessing magnesium's effects on sleep. The results suggested magnesium helped people fall asleep 17 minutes faster, but they didn't find that people slept any longer, and the trials were low quality. A 2022 study of nearly 4,000 participants found borderline improvement in sleep quality, but it was an observational trial. A systematic review in 2023 also saw benefits in observational trials but only contradictory results in randomized controlled trials. They also had few participants, and the trial duration was too short to yield meaningful answers.
The most recent systematic review, from 2024, investigated magnesium's impact on anxiety and sleep. Five out of eight studies found improvements in sleep, while two studies showed no benefit, and one had mixed findings.
A 2025 trial found that 28 days of supplementation (250 mg elemental magnesium as magnesium bisglycinate, with 1,523 mg glycine) resulted in modest but statistically significant improvements in insomnia severity index (ISI) scores (effect size d = 0.2) in adults with self-reported primary insomnia symptoms.
A systematic review confirmed that the quality of literature is substandard for physicians to make well-informed recommendations on usage of oral magnesium for older adults with insomnia.
Evidence strength: Preliminary to weak for dedicated RCT evidence. While observational data and preclinical work are suggestive, the few RCTs conducted to date are small, short in duration, and inconsistent in design. Sleep-related effects cannot be definitively confirmed from current evidence.
A 2017 systematic review concluded that about half the studies looking at magnesium and anxiety found a positive effect, but the studies were poor quality. A slightly larger trial similarly found improvements in anxiety and stress symptoms, and a 2020 systematic review found benefits for mild depression symptoms and anxiety. But the benefits did not show up in studies specifically in people with panic disorder or generalized anxiety disorder.
A 2024 systematic review found that five out of seven studies showed improvements in anxiety reported by the participants.
A small study in 2022 found that open-heart surgery patients who received magnesium had lower levels of anxiety and depression, suggesting a short-term benefit following anxiety-inducing experiences.
Evidence strength: Weak to preliminary. Most RCTs in this area are small and of low methodological quality. The evidence does not currently support magnesium supplementation as a treatment for diagnosed anxiety disorders.
Low magnesium status has been associated with neurological dysfunction, particularly migraines. Magnesium modulates neuronal excitability through voltage-gated calcium antagonism and NMDA receptor blockade, thereby attenuating cortical spreading depression and trigeminovascular activation, both core migraine mechanisms. Observational studies have reported lower circulating magnesium concentrations in migraine patients.
Accumulated evidence from case reports, case-control studies, observational studies, and randomized, placebo-controlled trials has shown the effectiveness of magnesium supplementation in alleviating migraine, both acutely and chronically.
Magnesium supplementation reduced migraine attacks (mean difference = −2.51), severity (mean difference = −0.88), and the monthly migraine days (mean difference = −1.66) compared with the control group in a systematic review and dose-response meta-analysis of randomized controlled trials.
One systematic review used six randomized controlled trials (RCTs) to evaluate the use of oral magnesium supplementation as prophylaxis in migraine, published between 1991 and 2021.
The National Headache Foundation suggests a daily dose of 400–600 mg of magnesium to reduce the frequency of migraine attacks; however, because this is greater than the RDA, it may lead to side effects (e.g., muscle weakness, diarrhea) in some people and may not be safe with certain medical conditions. They recommend discussing the use of high-dosage magnesium supplements with a physician.
For acute intravenous use, a meta-analysis of five RCTs totaling 295 patients found that the percentage of patients who experienced relief from headache at 30 minutes was 7% lower in the magnesium groups compared with controls, and the percentage who experienced side effects or adverse events was greater in the magnesium groups by 37%.
Evidence strength: Moderate for oral prophylaxis. Meta-analyses of RCTs suggest reduction in migraine frequency and severity with oral supplementation. Evidence for acute IV treatment in emergency settings is mixed and limited by small sample sizes.
Magnesium is involved in bone formation and influences the activities of osteoblasts and osteoclasts. Magnesium also affects the concentrations of both parathyroid hormone and the active form of vitamin D, which are major regulators of bone homeostasis.
Osteoporosis is an area where magnesium plays a role in the development of healthy bones. People with higher levels of magnesium might have a higher bone mineral density. This is important in helping reduce the risk of bone fractures associated with osteoporosis.
One short-term study found that 290 mg/day elemental magnesium (as magnesium citrate) for 30 days in 20 postmenopausal women with osteoporosis suppressed bone turnover compared with placebo, suggesting that bone loss decreased. Diets that provide the recommended levels of magnesium enhance bone health, but further research is needed to elucidate the role of magnesium in the prevention and management of osteoporosis.
Other studies have reported finding low serum magnesium levels among women with osteoporosis. However, more research is needed to determine whether magnesium supplements can help prevent or manage osteoporosis.
Future well-designed, long-term clinical studies are needed to better define dose-response relationships, to optimize supplementation strategies, and to determine the extent to which magnesium should be incorporated into standard prevention and treatment approaches for osteoporosis.
Evidence strength: Preliminary. Associations between magnesium status and bone density are epidemiologically consistent, but clinical trial evidence for supplementation outcomes is limited and short-term. No definitive RCT evidence currently supports magnesium supplementation as a standalone intervention for osteoporosis management.
Among 889 participants across 17 RCTs (mean age: 46 years; females: 62.5%) in a 2022 meta-analysis, generally a low risk of bias was present. Magnesium supplementation significantly decreased serum C-reactive protein (CRP) and increased nitric oxide (NO) levels.
Evidence strength: Moderate for biomarker reduction (CRP, NO). Clinical relevance of these biomarker changes for hard endpoints such as morbidity or mortality requires further investigation in longer-term trials.
Despite magnesium's essential roles, magnesium deficiency remains common worldwide, driven by inadequate dietary intake, chronic diseases, medication use, and lifestyle factors. Low magnesium status is associated with hypertension, type 2 diabetes, osteoporosis, migraines, depression, and chronic inflammation, whereas sufficient intake supports cardiometabolic resilience, skeletal strength, neurological stability, and healthy aging.
Level I evidence supports the use of magnesium in the prevention and treatment of many common health conditions including migraine headache, metabolic syndrome, diabetes, hyperlipidemia, asthma, premenstrual syndrome, preeclampsia, and various cardiac arrhythmias.
Emerging evidence confirms that nearly two-thirds of the population in the western world is not achieving the recommended daily allowance for magnesium, a deficiency problem contributing to various health conditions.
Early signs and symptoms of magnesium deficiency include loss of appetite, nausea, vomiting, fatigue, and weakness. As magnesium deficiency worsens, numbness, tingling, muscle contractions and cramps, seizures, personality changes, abnormal heart rhythms, and coronary spasms can occur. Severe magnesium deficiency can disrupt mineral homeostasis and cause hypocalcemia (low serum calcium levels) or hypokalemia (low serum potassium levels).
The diets of most people in the United States provide less than the recommended amounts of magnesium. Men older than 70 and teenage girls are most likely to have low intakes of magnesium.
It is estimated that between 56 and 68% of Americans do not obtain enough magnesium in their diet on a daily basis to meet the recommended daily allowance.
As we age, magnesium absorption and retention can decrease, leading to deficiency and health consequences. Older people are more susceptible to magnesium deficiency due to factors like decreased absorption from food, increased medication use (diuretics can deplete magnesium), and potential dietary restrictions.
The Recommended Dietary Allowance (RDA) for magnesium varies depending on age, sex, and life stage. The RDA for adult men is 400–420 mg/day, while for adult women it is 310–320 mg/day. During pregnancy and lactation, magnesium requirements increase to support maternal and fetal health.
Pregnancy requires about 350–360 mg daily and lactation, 310–320 mg. The Tolerable Upper Intake Level (UL) for magnesium is 350 milligrams from supplements only.
The Food and Nutrition Board (FNB) has established ULs for supplemental magnesium for healthy infants, children, and adults. For many age groups, the UL appears to be lower than the RDA. This occurs because the RDAs include magnesium from all sources — food, beverages, dietary supplements, and medications — while the ULs only include magnesium from dietary supplements and medications and do not include magnesium found naturally in food and beverages.
Data indicate that doses above the current UL for magnesium supplements can be consumed without adverse events. These updated data suggest that increasing the tolerable upper intake level for magnesium supplements is safe and may decrease the prevalence of individuals not meeting their need for this nutrient, which contributes to protection against numerous chronic diseases.
High-dose supplements can lead to diarrhea, nausea, and cramping in some people. Extra magnesium from food is safe because the kidneys will eliminate excess amounts in urine.
Magnesium supplements can cause nausea, cramps, and diarrhea. Magnesium supplements often cause softening of stool and are used for this purpose. The most common side effects of magnesium are stomach-related issues. Side effects usually occur at higher doses and are also more common with inorganic forms of magnesium, such as magnesium oxide.
One meta-analysis found only minor differences in gastrointestinal disturbances between groups given placebo versus 520 mg Mg/day, but withdrawals were not significantly different between groups. Another meta-analysis found that 3 of 13 studies (at doses of 120–973 mg/day) reported diarrhea that led to study withdrawal.
Several drugs including diuretics and proton-pump inhibitors can cause magnesium loss and hypomagnesemia. Magnesium and drugs use the same transport and metabolism pathways in the body for their intestinal absorption, metabolism, and elimination. This means that when one or more drugs are taken, there is always a potential risk of interaction with magnesium status. Consequently, the action of a drug may be adversely affected by magnesium — for example, magnesium, calcium, and zinc can interfere with the gastrointestinal absorption of tetracycline antibiotics — and simultaneously the physiological function of magnesium may be impaired by a drug (e.g., diuretics inducing renal magnesium loss).
Certain groups of people are more likely than others to have magnesium inadequacy. These include older adults (due to decreased absorption), individuals with gastrointestinal disorders, those with type 2 diabetes, people with alcohol dependence, and individuals on certain long-term medications as described above.
Hypermagnesemia (excess magnesium) from supplemental intake is rare in individuals with normal kidney function because the kidneys efficiently excrete excess magnesium. Signs of a magnesium overdose can include nausea, diarrhea, low blood pressure, muscle weakness, and fatigue. At very high doses, magnesium can be fatal. Risk is substantially elevated in individuals with impaired renal function.
Condiciones de salud que magnesio puede ayudar a apoyar.
Magnesium plays a direct regulatory role in HPA axis function; deficiency increases ACTH release, elevates stress hormones, and worsens anxiety. Chronic stress depletes magnesium, creating a feedback cycle that exacerbates adrenal fatigue symptoms. Supplementation is cited in peer-reviewed and integrative medicine literature as a core adrenal support nutrient.
Magnesium deficiency is consistently associated with elevated oxidative stress markers and weakened antioxidant defenses across human and animal studies. Mechanistically, low Mg²⁺ promotes mitochondrial dysfunction, inflammation, and excessive reactive oxygen species production. However, a 2025 systematic review and meta-analysis found that magnesium supplementation did not produce conclusive improvement across standard oxidative stress biomarkers (TAC, MDA, GSH), though it did significantly reduce CRP.
Magnesium is an essential mineral with multiple RCTs and systematic reviews supporting modest anxiolytic effects, particularly in individuals with low magnesium status. It acts as an NMDA receptor antagonist, reduces glutamate-mediated excitotoxicity, and supports GABA signaling. Systematic reviews consistently find positive effects in anxious, PMS, and mildly stressed populations, though effect sizes are variable.
Magnesium supplementation significantly reduces arterial stiffness as measured by pulse wave velocity (PWV). A 24-week RCT with 350 mg/day magnesium citrate reduced PWV from 9.1 to 8.3 m/s versus placebo without changing blood pressure. Magnesium also plays a role in endothelial function, participates in vascular calcification prevention, and improves flow-mediated dilation.
Magnesium plays a recognized role in bronchial smooth muscle relaxation and is used intravenously in acute severe asthma exacerbations in clinical practice. A systematic review and meta-analysis of 8 RCTs (917 patients) found oral magnesium supplementation improved FEV1 at 8 weeks. Low serum magnesium levels correlate with greater asthma severity and poor bronchodilator response.
Magnesium is involved in over 350 enzymatic reactions including ATP synthesis, muscle contraction, and protein synthesis. Athletes lose magnesium through sweat, and deficiency impairs performance. A systematic review identified magnesium as having among the strongest quality evidence for mineral supplementation in athletic performance.
Magnesium levels correlate inversely with ADHD symptom severity, and supplementation—often combined with vitamin B6—has shown reductions in hyperactivity and behavioral problems in children with ADHD in multiple RCTs. A 2019 meta-analysis confirmed significantly lower magnesium levels in ADHD versus controls. Typical studied doses are 6 mg/kg/day in children.
Magnesium has emerging evidence for supporting bladder health in overactive bladder (OAB) and interstitial cystitis contexts. A 2025 NHANES analysis found each one-point increase in magnesium depletion score was associated with 9% higher odds of OAB. A clinical trial showed magnesium hydroxide helped women with sensory urgency and detrusor instability. Magnesium relaxes smooth muscle and regulates nerve signals.
Magnesium supplementation has been shown in multiple RCTs and meta-analyses to modestly but significantly reduce blood pressure, particularly in magnesium-deficient or hypertensive individuals. A 2021 systematic review of 49 clinical trials confirmed antihypertensive effects. Mechanisms include vasodilation, calcium channel antagonism, and RAAS modulation.
Magnesium is an essential mineral involved in over 300 enzymatic reactions, including glucose metabolism and insulin signaling. Multiple systematic reviews and meta-analyses of RCTs confirm that magnesium supplementation significantly reduces fasting blood glucose and modestly improves HbA1c in T2DM patients, particularly those with low baseline magnesium.
Magnesium, particularly as magnesium hydroxide, is used in natural deodorant formulations to control body odor by raising underarm skin pH, creating an inhospitable environment for odor-producing bacteria. A study in the Journal of Cosmetic Dermatology found magnesium hydroxide effective at reducing body odor without disrupting the skin microbiome. A clinical study with a magnesium-based formulation (CareMag® D) showed over 40% reduction in malodor with 84% of participants reporting long-lasting protection.
Magnesium is an essential cofactor in bone mineral metabolism, enzyme activity for bone matrix synthesis, and is required for vitamin D activation. Observational data from large cohort studies found higher magnesium intake associated with 2–3% greater bone density in women. Clinical trials including the COMB study show supplementation may attenuate bone loss.
Magnesium is essential for over 300 enzymatic reactions and plays a critical role in synaptic plasticity, NMDA receptor function, and neurotransmitter synthesis. A study of 2,466 adults aged 60+ found higher magnesium levels associated with significantly better attention and memory. Low magnesium is linked to reduced cognitive function, neuroinflammation, and impaired stress responses—all contributors to brain fog.
Magnesium is an essential mineral involved in over 300 biochemical reactions including ATP production, cortisol regulation, and nervous system function. Chronic stress increases urinary magnesium excretion and depletes tissue stores, contributing to the fatigue, cognitive fog, and muscle tension hallmarks of burnout. Clinical and mechanistic evidence supports magnesium supplementation for stress resilience and fatigue reduction in depleted individuals.
Magnesium is an essential mineral that modulates NMDA glutamate receptors and enhances GABAergic availability, reducing neuronal excitability. A 2017 PMC systematic review of 18 studies found consistent evidence that supplementation reduces subjective anxiety, particularly in vulnerable populations. A 2024 systematic review confirmed improvements in self-reported anxiety and sleep quality across interventional trials. Typical doses: 100–400 mg elemental magnesium/day.
Magnesium deficiency is common in celiac disease and may persist even on long-term, compliant gluten-free diet because gluten-free cereal products contain lower magnesium than conventional counterparts. The 2013 ACG guidelines and a 2013 systematic review explicitly recognize magnesium deficiency as relevant in CeD and recommend a magnesium-enriched diet or supplementation for persistent deficiency.
Magnesium is required for the stability and enzymatic activity of ATP itself (MgATP is the biologically active form), and serves as a cofactor in glycolysis, the TCA cycle, and oxidative phosphorylation. Without adequate magnesium, cellular energy production across all pathways is compromised.
Magnesium is an essential cofactor for bone formation, vitamin D activation, and calcium metabolism. EFSA has recognized sufficient evidence that dietary magnesium contributes to the maintenance of bones and teeth. A PMC review on school-age children specifically lists magnesium as a critical mineral for optimizing bone mass.
Magnesium is essential for over 300 enzymatic reactions including energy production, protein synthesis, muscle and nerve function, and bone development. IOM RDAs for children are 80–240 mg/day. NIH ODS-funded label analysis found magnesium present in all children's MVMs though below RDA, and it is a standard mineral in pediatric multivitamin-mineral products.
Magnesium is a cofactor in over 300 enzymatic reactions including ATP synthesis, glucose metabolism, and protein production. Deficiency is associated with fatigue and muscle weakness. EFSA authorizes a health claim for magnesium contributing to reduction of tiredness and fatigue. The 2020 Tardy et al. review documents magnesium's central role in energy-yielding metabolism and fatigue.
Multiple meta-analyses of randomized controlled trials demonstrate that magnesium deficiency promotes chronic low-grade inflammation, and that supplementation significantly reduces key inflammatory markers—particularly serum C-reactive protein (CRP). The core mechanistic link involves magnesium's role in regulating intracellular calcium and modulating pro-inflammatory cytokine pathways. Evidence is strongest in populations with pre-existing low magnesium status, such as those with metabolic syndrome. Results across RCTs remain somewhat inconsistent for markers like IL-6, and effect sizes are modest.
Magnesium deficiency is linked to chronic migraine and musculoskeletal pain. Accumulated evidence from RCTs, case-control, and observational studies shows magnesium supplementation alleviates migraine frequency and severity. It modulates NMDA receptor activity, reducing central sensitization relevant to chronic pain.
Magnesium undergoes circadian oscillations of intracellular concentration in eukaryotic cells, and these rhythms are integral to cellular timekeeping. A 2016 Nature study demonstrated daily magnesium fluxes regulate cellular circadian timekeeping and energy balance. Magnesium deficiency disrupts clock gene expression (PER2) and sleep architecture.
Magnesium plays a well-documented role in neurological function, and both low dietary intake and low serum magnesium are independently associated with greater risk of cognitive decline and dementia in epidemiological studies. A 2024 systematic review and meta-analysis found consistent U-shaped associations between serum magnesium and all-cause dementia, suggesting an optimal serum level near 0.85 mmol/L. The brain-penetrant form, magnesium L-threonate, has shown cognitive benefits in multiple small RCTs in older adults. Overall evidence is promising but robust long-term intervention trials remain limited.
Magnesium levels fall acutely after concussion/TBI, and its deficiency exacerbates excitotoxicity and neuronal death. Multiple peer-reviewed reviews identify magnesium as one of the most evidence-supported minerals for TBI recovery improvement in preclinical models and in class III human studies. A 2022 Frontiers in Nutrition systematic review found magnesium supplementation effective in improving neurological and cognitive recovery in mTBI. It stabilizes NMDA receptors, reduces excitotoxicity, and attenuates neuroinflammation.
Magnesium-based compounds (magnesium hydroxide, magnesium oxide) are recognized first-line osmotic laxatives in AGA and ACG clinical guidelines for chronic constipation. A large NHANES analysis found dietary magnesium inversely associated with chronic constipation (OR 0.39 for highest vs. lowest quartile in men). Magnesium draws water osmotically into the bowel and stimulates cholecystokinin-mediated gut motility.
Magnesium deficiency is common in COPD patients. A 2024 systematic review found magnesium supplementation may reduce inflammation levels in COPD patients. Intravenous magnesium sulfate is used in severe acute exacerbations for its bronchodilatory effect. A broad PMC review lists magnesium among micronutrients protective against chronic lung disease.
Magnesium deficiency is prevalent in Crohn's disease, confirmed in a 2024 PRISMA-compliant systematic review of eight studies (453 CD patients). Serum magnesium was significantly lower in CD patients versus controls, correlated with elevated CRP (disease activity), and hypomagnesemia prevalence reached up to 50% in one study. Supplementation may improve CD management and remission.
Magnesium deficiency is associated with increased risk of depression. Multiple clinical studies have found supplementation reduces depressive symptoms, and a 2017 randomized clinical trial (n=126) found magnesium chloride (248 mg/day) effective for mild-to-moderate depression, comparable to antidepressants. It modulates NMDA receptor activity and HPA axis function.
Magnesium is a primary intracellular electrolyte and cofactor for over 300 enzymatic reactions. NIH/StatPearls and MedlinePlus identify it as one of the seven major electrolytes. It is required for sodium-potassium ATPase function, making it foundational to all electrolyte transport. Hypomagnesemia commonly co-occurs with hypokalemia and hypocalcemia, and clinical management of electrolyte imbalance routinely addresses magnesium status.
Magnesium is an essential mineral critical for serotonin, GABA, and dopamine synthesis and nervous system regulation. Multiple RCTs demonstrate that supplementation reduces anxiety and stress, particularly in deficient individuals. A clinical trial found magnesium + vitamin B6 significantly superior to magnesium alone for severe stress in adults with low magnesemia.
Magnesium is a widely studied muscle relaxant and anti-inflammatory mineral evaluated in endometriosis for relieving dysmenorrhea and pelvic pain. It is recommended in traditional integrative approaches for uterine muscle spasm. One single RCT on magnesium for endometriosis pain did not confirm effectiveness by itself, but animal studies support its antiangiogenic properties.
Magnesium plays a central role in ATP production and utilization: all ATP in cells exists as an Mg2+-ATP complex, and magnesium is a cofactor for over 300 enzymatic reactions including those in glycolysis and oxidative phosphorylation. EFSA authorizes health claims that magnesium contributes to normal energy-yielding metabolism and to the reduction of tiredness and fatigue.
Magnesium is a well-recognized anticonvulsant agent, with intravenous magnesium an established treatment for eclamptic seizures. Magnesium deficiency is associated with increased epilepsy risk, and studies suggest that children with low serum magnesium have up to 75% response rates to magnesium supplementation with reduced seizure frequency. Magnesium helps maintain neuronal connections and inhibits excessive firing.
Magnesium is an essential cofactor for hundreds of enzymatic reactions and plays a role in insulin sensitivity and hormone regulation. In PCOS, magnesium co-supplementation (with zinc, calcium, vitamin D) improves insulin sensitivity, CRP, lipid profiles, and glucose metabolism relevant to fertility. Magnesium gaps are documented in infertile women.
Multiple studies show fibromyalgia patients frequently have lower magnesium levels, and supplementation has demonstrated benefit in some trials. A 2021 literature review (Boulis et al., Sage Journals) surveyed multiple correlational and interventional studies. A 2022 double-blind RCT found magnesium significantly reduced mild/moderate stress and pain severity in FM patients versus placebo. Magnesium citrate combined with amitriptyline has also been evaluated as adjunct therapy.
Magnesium is an essential mineral required for over 300 enzymatic reactions, including those involved in collagen synthesis, cartilage matrix maintenance, and muscle relaxation. Low magnesium status is associated with higher levels of inflammatory markers (CRP, IL-6) and increased joint stiffness. Supplementation supports muscle flexibility and reduces cramps that impair joint mobility.
Magnesium deficiency is common in children with ADHD. An open-label study in 40 ADHD children using magnesium-B6 (6 mg/kg/day Mg) for ≥8 weeks significantly reduced hyperactivity, aggression, and improved school attention; symptoms returned when treatment was stopped. A systematic review found mixed results, with greatest benefit in confirmed deficiency states.
Clinical trials, particularly with the highly brain-permeable form magnesium L-threonate (MgT), demonstrate improvements in attention and executive function. A 2026 randomized double-blind placebo-controlled trial found MgT at 1 g twice daily significantly improved overall cognitive performance on the NIH Total Cognition Composite (p=0.043), with notable gains in working memory and reaction time. Population-based data from NHANES (n=2,508 adults ≥60) further show that higher magnesium intake is independently associated with higher global cognitive scores. Most standard oral magnesium forms have limited blood-brain barrier permeability, which may limit cognitive-relevant effects.
Magnesium has been studied for glaucoma, particularly normal-tension glaucoma, based on its role in vascular regulation and optic nerve blood flow. A clinical study of oral magnesium citrate 300 mg/day in NTG patients was conducted. A 2018 systematic review listed magnesium among trace elements with putative protective effects in glaucoma.
Magnesium is an essential mineral involved in over 300 biochemical reactions and has documented gut-brain axis relevance. It modulates the HPA axis, supports GABA receptor function, reduces neuroinflammation, and influences gut microbiota composition. Magnesium deficiency is associated with anxiety and depression; supplementation in magnesium-deficient individuals improves mood and stress resilience.
Magnesium deficiency has been associated with migraine pathophysiology, and oral magnesium supplementation is rated Level B (probably effective) for migraine prevention by the AAN and AHS. Several RCTs support reduced attack frequency with daily supplementation. Intravenous magnesium is also used acutely.
Magnesium is involved in over 300 enzymatic reactions and is directly linked to all 12 recognized hallmarks of aging, including genomic instability, telomere attrition, mitochondrial dysfunction, and inflammaging. A 2024 PMC review identifies magnesium inadequacy as a contributor to accelerated aging and proposes maintaining optimal magnesium levels as a safe strategy for promoting healthy aging.
Magnesium is an essential macromineral involved in over 300 enzymatic reactions, protein synthesis, muscle and nerve function, and bone development. It is a recognized nutrient for pediatric growth and development included in the IOM Dietary Reference Intakes for children. Adequate magnesium intake supports bone mineralization alongside calcium and vitamin D during childhood skeletal growth.
Magnesium has been studied in both noise-induced hearing loss (NIHL) and tinnitus. Israeli military studies showed that soldiers taking magnesium before noise exposure experienced significantly less permanent hearing loss than controls. Magnesium's vasodilatory and neuroprotective effects are believed to protect cochlear hair cells during acoustic trauma. It also shows some evidence for reducing tinnitus severity.
Magnesium has substantial clinical and epidemiological evidence supporting its role in cardiovascular health. Higher dietary and circulating magnesium levels are inversely associated with risks of coronary heart disease, stroke, and total cardiovascular disease. Magnesium supplementation produces modest but significant reductions in blood pressure, and magnesium deficiency is linked to cardiac arrhythmias including atrial fibrillation. The evidence base spans multiple large meta-analyses and randomized controlled trials.
Magnesium is a well-established cofactor in cardiac electrophysiology, modulating ion channel exchanges and action potentials. Hypomagnesemia is strongly linked to ventricular and supraventricular arrhythmias. A meta-analysis of 22 studies found magnesium sulfate significantly reduced both ventricular arrhythmias (11.88% vs 24.24%) and supraventricular arrhythmias compared to placebo. Intravenous magnesium is a recognized treatment for torsades de pointes, digitalis-induced arrhythmias, and multifocal atrial tachycardia.
Magnesium modulates HPA axis activity bidirectionally: deficiency enhances HPA reactivity by raising CRH, ACTH, and cortisol, while chronic stress depletes magnesium. The 2025 American Journal of Medicine review identifies magnesium deficiency as impairing adrenal function and recommends 300–400 mg/day supplementation for HPA axis support during stress.
Magnesium is essential for insulin receptor signaling and glucose metabolism; deficiency impairs insulin action and is associated with dysglycemia. A 2016 meta-analysis of 18 RCTs found magnesium supplementation significantly reduced fasting blood glucose (-4.07 mg/dL) and HbA1c (-0.32%) in diabetic or pre-diabetic subjects. Correcting magnesium deficiency supports normalized glucose homeostasis relevant to hypoglycemia prevention.
Magnesium deficiency is associated with elevated thyroid antibodies and increased Hashimoto's disease risk, and it supports iodine uptake into the thyroid gland. A narrative review published in Cureus identified magnesium as an untapped mineral with potential clinical benefit in HT. Magnesium also reduces overall inflammation relevant to autoimmune thyroiditis.
Magnesium acts as a natural calcium antagonist that inhibits voltage-gated calcium channels in detrusor smooth muscle, reducing overactivity. A randomized trial found 55% of women with detrusor instability had subjective urinary urgency improvement with magnesium hydroxide. A 2025 large NHANES analysis (n=28,621) found each one-point increase in magnesium depletion score was associated with 9% higher odds of OAB.
Magnesium is an essential mineral involved in NMDA receptor regulation and melatonin synthesis, both relevant to sleep. Clinical studies support supplementation for improving sleep quality, efficiency, and duration, particularly in older adults or magnesium-deficient individuals.
Magnesium supplementation has been shown in systematic reviews and meta-analyses to significantly improve HOMA-IR in diabetic and non-diabetic individuals. A meta-analysis of RCTs found a significant effect on HOMA-IR (WMD: −0.67; p = 0.013), and magnesium deficiency—highly prevalent in T2DM patients—is inversely correlated with insulin sensitivity. Supplementation for more than 4 months shows the most consistent improvements.
Magnesium is a well-established inhibitor of calcium oxalate crystallization in urine and has been studied in multiple clinical trials for kidney stone prevention. A landmark double-blind RCT of potassium-magnesium citrate (n=64, up to 3 years) showed new stones formed in only 12.9% of treated subjects vs. 63.6% on placebo (relative risk 0.16). Magnesium supplementation also reduces urinary oxalate excretion and raises urinary citrate, both key protective factors against stone formation.
Magnesium is a required cofactor for diamine oxidase (DAO) enzyme activity, which degrades histamine central to MCAS. Deficiency is associated with increased mast cell reactivity and amplified histamine-related symptoms. Integrative MCAS practitioners report near-universal deficiency in their patient populations and list magnesium among the most critical nutrients for MCAS management.
Multiple RCTs demonstrate that magnesium L-threonate supplementation improves episodic and working memory in adults. A 12-week RCT in older adults with mild cognitive impairment found that MgT produced a cognitive score improvement equivalent to approximately 9 years of cognitive rejuvenation. The mechanistic basis involves magnesium's regulation of NMDA receptor plasticity and support for synaptic density, processes central to memory encoding and consolidation.
Magnesium is involved in over 300 biochemical reactions and is particularly relevant during menopause for sleep quality, bone health, and mood regulation. NIH data show it is deficient in the majority of women. A 2025 systematic review identified magnesium as critical for counteracting the heightened inflammatory and cardiovascular burden of menopause.
Multiple clinical trials and a Cochrane-linked review confirm magnesium is more effective than placebo for dysmenorrhea, reducing uterine muscle contractility by blocking calcium-dependent smooth muscle contraction. A systematic review and meta-analysis found magnesium contributes effectively to primary dysmenorrhea pain management. Traditional and integrative medicine have long recommended magnesium for menstrual cramping.
Magnesium is a cofactor in over 300 enzymatic reactions, including ATP synthesis and NMDA receptor modulation. Suboptimal magnesium status impairs cognitive performance and energy, and EU health claims recognize its contribution to normal psychological function and reduction of tiredness.
Substantial clinical and epidemiological evidence links magnesium status to metabolic syndrome (MetS). Low dietary magnesium intake and low serum magnesium are consistently associated with increased MetS risk across large meta-analyses. Supplementation has demonstrated reductions in CRP, fasting glucose, and blood pressure in RCTs, though effect sizes are modest and evidence on lipid profiles and overall MetS reversal remains mixed.
Magnesium is a well-established cofactor in over 300–600 enzymatic reactions central to energy metabolism, including glycolysis, the Krebs cycle, and ATP synthesis. Clinical and epidemiological evidence links adequate magnesium status to improved insulin sensitivity, glucose regulation, and reduced risk of metabolic syndrome. Meta-analyses of prospective cohort studies show high magnesium intake is associated with a 21–39% lower odds of metabolic syndrome compared to low intake. Some RCT evidence supports improvements in insulin resistance markers, though individual trial results remain mixed.
Magnesium is a required cofactor for methionine adenosyltransferase (MAT), the ATP-dependent enzyme that converts methionine to SAMe. Multiple methylation-cycle references confirm Mg2+ is essential for SAMe synthesis and for other methylation-pathway enzymes. It is listed as a key methylation support mineral in multiple authoritative methylation references.
Magnesium is one of the most evidence-backed supplements for migraine prevention. AAN/AHS guidelines granted it Level B evidence (probably effective). A 2024 systematic review and meta-analysis found magnesium supplementation significantly reduced migraine attack frequency, severity, and monthly migraine days versus placebo. Intravenous magnesium is also used for acute migraine.
Magnesium is required for over 300 enzymatic reactions including several steps of the Krebs cycle, and ATP itself exists primarily as the Mg-ATP complex in cells. Magnesium deficiency directly impairs mitochondrial function and is rapidly depleted by oxidative stress. Scientific evidence supports magnesium's role in supporting mitochondrial ATP synthesis and energy metabolism.
Magnesium was used as a co-treatment with 5-HTP (Griffonia simplicifolia) in the Esposito et al. (J Med Food 2015) open-label pediatric trial, which showed significant motion sickness symptom reduction over three months. Magnesium's relevance is supported by evidence that serum Mg2+ levels are associated with vestibular migraine, a condition closely linked to motion sickness susceptibility. Its role may include modulating serotonergic and NMDA receptor activity in vestibular nuclei.
Magnesium is the most studied mineral supplement for skeletal muscle cramps. Cochrane reviews of multiple RCTs found it unlikely to provide meaningful cramp prophylaxis in older adults with idiopathic cramps (moderate-certainty evidence), but evidence for pregnancy-associated leg cramps remains conflicting. Magnesium deficiency impairs muscle relaxation, as muscles contract normally but struggle to fully release when levels are low.
Magnesium is an essential mineral and cofactor for ATP synthesis, muscle protein synthesis, and over 300 enzymatic reactions. It suppresses pro-inflammatory cytokines (IL-6, TNF-α) relevant to exercise recovery; deficiency is associated with impaired muscle repair, increased cramps, and elevated post-exercise oxidative stress markers.
A 2024 systematic review in the Journal of Translational Medicine (4 RCTs) found magnesium supplementation reduced muscle soreness, improved performance and recovery, and exerted a protective effect on muscle damage in physically active individuals. Magnesium regulates muscle contraction via intracellular calcium transport. Doses of 350–500 mg/day have been studied. Exercise may increase magnesium requirements by 10–20%.
Magnesium is a cofactor in over 300 enzymatic reactions including protein synthesis required for nail plate formation; vertical ridges in nails are associated with magnesium deficiency. Healthline and PMC nutrition reviews identify magnesium deficiency as a contributing factor to nail abnormalities. It was part of a multivitamin formula that demonstrated positive impact on nail growth in a clinical study (PMC 11961095).
Magnesium is an essential mineral that plays a critical role in nervous system function as a natural NMDA receptor antagonist, modulating synaptic transmission and neuronal excitability. Deficiency is associated with increased risk of neurological symptoms, and supplementation supports normal nerve function.
Magnesium plays a critical role in nerve excitability by blocking NMDA receptors and regulating calcium and potassium channels; deficiency is associated with heightened neuropathic pain and peripheral nerve hyperexcitability. Clinical evidence supports magnesium supplementation for nerve excitability modulation, neuropathic pain reduction, and sleep improvement in neuropathy patients. Deficiency is common in diabetic patients and clinically recognized as worsening neuropathy symptoms.
Magnesium is an essential mineral cofactor in dopamine synthesis (tyrosine hydroxylase) and a physiological blocker of NMDA glutamate receptor channels. Deficiency is linked to depression and anxiety. A 2017 RCT showed 248 mg/day magnesium significantly reduced both PHQ-9 depression and GAD-7 anxiety scores. It supports inhibitory-excitatory neurotransmitter balance.
Magnesium is the second most abundant mineral in bone and is essential for vitamin D activation and calcium metabolism. Low magnesium is associated with increased osteoporosis risk, and supplementation (as citrate, carbonate, or oxide) may protect bone density and reduce fracture risk per a 2021 research review. Magnesium deficiency promotes osteoclast activity and disrupts calcium homeostasis.
Magnesium depletion is significantly associated with overactive bladder in large population-based data (NHANES 2005–2018, n=28,621). Mechanistically, magnesium acts as a natural calcium antagonist, and deficiency leads to excess calcium influx causing involuntary detrusor contractions characteristic of OAB. An early clinical study also found magnesium supplementation had a positive effect on urinary frequency, urgency, and voiding difficulty.
Magnesium deficiency is associated with increased anxiety and heightened stress responses, and supplementation has been studied for stress and anxiety reduction. A 2017 systematic review found evidence that magnesium supplementation reduced subjective anxiety in vulnerable populations. Magnesium modulates anxiety via NMDA receptor antagonism, GABA-A potentiation, and reduction of glutamatergic hyperexcitability associated with panic.
Magnesium deficiency is common in PCOS and linked to insulin resistance. RCTs show magnesium oxide supplementation (250mg/day) reduced fasting insulin, HOMA-IR, total cholesterol, LDL, and fasting blood glucose in PCOS. When co-supplemented with zinc, calcium, and vitamin D, it significantly improved hirsutism scores, inflammation, and oxidative stress.
Magnesium is commonly used for perimenopausal symptoms including sleep disturbance, mood instability, muscle relaxation, and general hormonal balance. Evidence indicates it improves sleep and well-being during the menopause transition. An active 2026 clinical trial (NCT07235878) is specifically investigating magnesium hydroxide supplementation on perimenopausal symptoms.
Magnesium is a cofactor in over 300 enzymatic reactions including ATP synthesis, muscle contraction, and oxygen delivery, making it essential for physical endurance. Deficiency impairs performance and increases fatigability. Supplementation in deficient athletes improves VO2max, strength, and endurance outcomes. Magnesium is recognized by IOC and sport nutrition bodies as a priority micronutrient for endurance athletes.
Magnesium is identified in authoritative dietary reviews as a nutrient commonly deficient in picky eaters who avoid nuts, seeds, whole grains, and leafy greens. Insufficient magnesium intake is linked to sleep disturbances, mood changes, and impaired muscle function in children.
Magnesium deficiency has been implicated in PMS pathophysiology, with studies showing lower red blood cell magnesium in PMS patients. RCTs using magnesium pyrrolidone show preliminary benefit for premenstrual mood and fluid retention symptoms. A synergistic effect with vitamin B6 has been documented in a double-blind crossover RCT for anxiety-related PMS symptoms.
Magnesium is a cofactor in over 300 enzymatic reactions and plays critical roles in immune cell function, energy metabolism (ATP synthesis), and muscle function. Deficiency is common during illness and recovery. Supplementation supports post-illness restoration of energy and immune competence.
Magnesium is an essential mineral and cofactor for over 300 enzymatic reactions including protein synthesis and energy metabolism relevant to post-surgical recovery. Perioperative magnesium supplementation has been studied in clinical trials for reducing post-surgical pain, opioid consumption, and cardiac arrhythmias after surgery. It is included in perioperative nutrition protocols.
Magnesium supports over 300 enzymatic reactions including energy production and mitochondrial function, both compromised in post-viral fatigue. Clinical studies of post-COVID patients show magnesium deficiency is common, and supplementation is included in evidence-based post-viral recovery protocols. EFSA has granted health claims for magnesium in reduction of tiredness and fatigue.
Magnesium is commonly deficient in postpartum and breastfeeding women (>50% inadequacy per WIC data), contributing to muscle cramps, poor sleep, fatigue, and mood disturbances. The NIH ODS identifies it as a critical underconsumed nutrient for postpartum women. Magnesium supports muscle relaxation, nerve function, and sleep quality — key recovery domains in the postpartum period.
Magnesium is an essential mineral for muscle relaxation, bone development, and blood pressure regulation during pregnancy, with levels declining if unsupplemented. Inadequate magnesium intake is linked to gestational diabetes, preeclampsia, preterm birth, and low birthweight. A Cochrane review found magnesium supplementation was associated with significant reduction in low birthweight risk. NIH ODS lists magnesium among critical prenatal nutrients underconsumed by pregnant women.
Magnesium is an essential mineral involved in multiple enzymatic reactions relevant to hormone synthesis and HPA axis regulation. It supports progesterone production by reducing cortisol (which competes for pregnenolone as a precursor), supporting LH pulsatility, and facilitating the enzymatic conversion of cholesterol to pregnenolone. Magnesium deficiency is associated with PMS and luteal phase symptoms, and supplementation is an evidence-based treatment for PMS. Typical dose for hormonal support is 300–400 mg/day as magnesium glycinate.
Low serum magnesium levels are associated with greater RLS severity, particularly in pregnant women. A randomized controlled trial found magnesium oxide (250 mg/day) significantly improved both RLS symptom scores and sleep quality compared to placebo and was superior to vitamin B6. A 2024 systematic review of 10 RCTs confirmed magnesium as showing the strongest supplemental benefit.
Magnesium deficiency is linked to neuropathic pain and muscle spasm that can exacerbate sciatica. Magnesium supplementation has been associated with reduced muscle inflexibility and discomfort in sciatica patients. It acts as an NMDA receptor antagonist, blocking central sensitization relevant to chronic sciatic pain.
Magnesium is an essential cofactor in over 300 enzymatic reactions including ATP-dependent processes in osteoblasts, helps stabilize hydroxyapatite crystals, and controls PTH release. Nutritional deficiency in magnesium is identified in AIS patients alongside calcium and zinc, contributing to reduced bone formation and increased osteoclastic activity. It is consistently cited in scoliosis-focused nutrition literature and multisystem AIS reviews.
Magnesium is an essential mineral involved in over 300 enzyme reactions including serotonin synthesis, NMDA receptor regulation, and HPA axis stress response—all relevant to seasonal mood. Multiple peer-reviewed reviews and RCTs document magnesium's anxiolytic and antidepressant properties. A 2017 RCT (n=126) found 248 mg/day magnesium significantly reduced PHQ-9 depression scores. It is consistently listed among supplements relevant to mood disorders including SAD-related presentations.
A 2025 Mendelian Randomization study (Respiratory Medicine) confirmed a significant causal protective effect of magnesium against OSA (OR <1, p<0.05), with NHANES data showing a 64% increased likelihood of OSA in those with high magnesium depletion scores. A systematic review and meta-analysis found OSA patients had significantly lower serum magnesium levels (effect size −1.22, 95% CI: −2.24 to −0.21). Magnesium supports GABA activity, muscle relaxation, and anti-inflammatory pathways relevant to upper airway function.
Magnesium acts as an NMDA receptor antagonist and GABA-A agonist, mechanistically supporting sustained sleep continuity. A double-blind, placebo-controlled RCT in elderly insomniacs (500 mg/day, 8 weeks) found significant improvements in sleep efficiency, total sleep time, and early morning awakening alongside increased melatonin and reduced cortisol. Animal models show magnesium deficiency specifically increases wakefulness and reduces slow-wave sleep, reversed by reintroduction of the mineral.
Magnesium is an essential mineral that regulates NMDA glutamate receptors and GABA-A receptors, both central to sleep regulation. A systematic review and meta-analysis found magnesium supplementation reduced sleep onset latency by 17.36 minutes versus placebo in older adults with insomnia, though evidence quality was rated low-to-moderate.
Magnesium is an essential mineral that modulates NMDA receptor activity and GABA-A receptor function, supporting both CNS inhibitory tone and melatonin production. A systematic review and meta-analysis of RCTs found magnesium supplementation reduced sleep onset latency by 17.36 min (p=0.0006) vs. placebo in older adults with insomnia. A 2024 RCT (n=155; 250 mg elemental magnesium bisglycinate) confirmed improvements in insomnia severity in healthy adults with poor sleep. Evidence quality is rated low-to-moderate, with larger RCTs needed.
An essential mineral with a well-established role in stress physiology. Stress depletes magnesium, while low magnesium amplifies the stress response. A systematic review of 18 studies found beneficial effects on subjective anxiety in vulnerable populations. Magnesium regulates NMDA receptors and supports GABA activity.
Magnesium deficiency is associated with lower testosterone levels, and supplementation has been shown to increase free and total testosterone in athletes and sedentary men. A 2011 RCT found 450 mg/day of magnesium increased testosterone by approximately 24% over four weeks. Magnesium reduces SHBG binding affinity, thereby increasing bioavailable testosterone.
Magnesium is listed among key micronutrients influencing thyroid hormone synthesis and regulation. A 10-week RCT demonstrated that combined zinc, vitamin A, and magnesium supplementation significantly raised FT4 in hypothyroid patients. Magnesium deficiency has been associated with thyroid dysfunction, and supplementation may have a protective role against thyroid disorders.
Serum magnesium levels are measurably lower in people with tinnitus than in the general population. Magnesium protects cochlear hair cells from noise-induced damage by blocking calcium influx and reducing oxidative stress. A Phase 2 clinical trial found that magnesium supplementation reduced tinnitus-related handicap as measured by the THI, and preliminary studies show benefit on tinnitus perception.
Magnesium has been investigated in both clinical and preclinical contexts for TMJ and myogenic TMD. A randomized clinical study demonstrated local magnesium injection effectively reduced myofascial trigger point pain and improved mouth opening in masticatory muscles. Magnesium deficiency is linked to bruxism and orofacial pain through NMDA receptor modulation.
Magnesium is a trace substituent within enamel hydroxyapatite crystals and plays a role in crystal structure and enamel hardness. Magnesium chloride has been tested in remineralizing gel formulations alongside calcium glycerophosphate and xylitol, showing enamel ultrastructure restoration in clinical studies. It is also incorporated into strontium- and magnesium-doped hydroxyapatite remineralizing toothpastes.
The relationship between magnesium supplementation and triglycerides is clinically studied but results are mixed. Some systematic reviews report a trend toward triglyceride reduction with magnesium, particularly in diabetic or hypomagnesemic populations, while a 2017 meta-analysis of RCTs found no statistically significant effect on triglyceride concentrations. Mechanistically, magnesium influences lipid-metabolizing enzymes including lipoprotein lipase and HMG-CoA reductase.
Magnesium supports inner ear fluid homeostasis and has been investigated in migraine-associated vertigo given its established role in migraine prophylaxis. A meta-analysis in cardiac patients found magnesium orotate supplementation reduced dizziness risk by 78%. Magnesium is also a required co-factor for vitamin D activation, linking it indirectly to the BPPV-otoconia pathway. Direct evidence for vertigo reduction in isolation is limited but present in migraine-related dizziness contexts.
Magnesium is a key electrolyte that maintains optimal fluid balance and electrolyte homeostasis, and clinical evidence supports its role in reducing fluid retention specifically in PMS. A clinical study found magnesium supplementation alleviates PMS-associated fluid retention symptoms including bloating and extremity swelling. NIH MedlinePlus and StatPearls recognize magnesium as essential for fluid and electrolyte regulation.
Magnesium sulfate (Epsom salt) foot soaks are a widely recommended traditional home remedy for bunion pain and swelling. Soaking feet in Epsom salt (magnesium sulfate) dissolved in warm water for 15–20 minutes is specifically cited by podiatric and medical sources including MedicineNet for reducing bunion-associated inflammation and pain.
Magnesium is widely used traditionally to support children's sleep due to its well-established role in GABA receptor activation, melatonin production, and nervous system calming. Direct pediatric RCT evidence for insomnia is limited, but there is evidence it may aid children with restless legs syndrome. Plausible mechanisms are supported by adult clinical trial data showing improvements in sleep quality and efficiency.
Magnesium is an essential cofactor for hundreds of enzymatic reactions and participates in DNA synthesis and protein metabolism in hair follicle cells. A 2025 SAGE systematic review found magnesium deficiency associated with androgenetic alopecia progression alongside other micronutrient deficiencies. Direct clinical trials for isolated magnesium supplementation in hair loss are lacking.
Magnesium is cited by multiple institutional sources including Adam/SBRMC and integrative medicine databases as a supplement that opens blood vessels and may relax constricted blood vessels in Raynaud's. However, Adam/SBRMC explicitly notes there are no controlled scientific studies demonstrating its efficacy specifically for Raynaud's. It is recommended by some clinicians based on known cardiovascular vasodilatory properties. Scleroderma & Raynaud's UK lists it among supplements used for circulatory problems in Raynaud's.
Magnesium is an essential mineral involved in over 300 enzymatic reactions. It modulates NF-κB signaling and inflammation; magnesium deficiency is associated with increased inflammatory markers. ConsumerLab lists magnesium among supplements studied for RA and joint health, and use of magnesium supplementation increased significantly in RA patients over time in Australian rheumatology cohort data.
Sistemas corporales que magnesio puede ayudar a apoyar.
Volver